非小细胞肺癌脑转移药物治疗的研究进展

Progress of drugs in non-small cell lung cancer with brain metastasis

非小细胞肺癌（ NSCLC）是最常见的恶性肿瘤之一，也是导致癌症死亡的主要原因，其疗效欠佳、预后差，尤其是伴有脑转移患者。 NSCLC伴脑转移患者生活质量差，预后不良，自然中位生存期仅为1～2个月，全脑放射治疗虽然在一定程度上改善了患者的生活质量，延长了患者的生存期，但疗效仍不理想。近年来围绕培美曲塞、替莫唑胺以及表皮生长因子受体酪氨酸激酶抑制剂（ EGFR-TKIs）开展了一些研究，并取得了一定的成果。本文就针对培美曲塞、替莫唑胺及EGFR-TKIs等抗肿瘤药物在NSCLC伴脑转移中的研究进展进行综述。

Non-small cell lung cancer（ NSCLC） is one of the most common malignant tumor and a major cause of death from cancer. NSCLC patients often poorly responds to chemotherapy and has a relatively poor prognosis, especially in those patients with brain metastases. NSCLC patients with brain metastases have poor prognosis and worse quality of life;the natural median survival time is only 1-2 months. To some extent,whole brain radiation therapy improves quality of life and prolongs the survival time in NSCLC pa-tients with brain metastases;but the curative effects are still unsatisfactory.In recent years,some research around pemetrexed,temozolo-mide and epidermal growth factor receptor-tyrosine kinase inhibitors（ EGFR-TKIs） are conducted and achieves certain results. In this paper,we review the progress of drugs in NSCLC with brain metastasis.